in this activity, participants:
determine that, to assure safety, optimum IV iron
the anemia of chronic kidney disease is guided by theoretical,
laboratory and clinical assessment of potential adverse effects
recognize that rate of administration determines, in part,
the total iron which can be safely administered in one dose.
consider that the total iron dose which can be administered
in a single setting differs among IV iron agents
dextran, ferric gluconate, and iron sucrose.
Will summarize key findings in the US Clinical Trials of Iron Sucrose,
and relate those findings to previous literature
consider that high ferritin levels, iron excess and iron deficiency
are each associated with poor patient outcomes
realize that maintenance IV iron protocols more
prevent iron deficiency and that such protocols should aim to
avoid ferritin levels above 800 ng/ml.
Assistant Clinical Professor of Medicine
North Central Kidney Institute
University of North Dakota Medical School
Sioux Falls, SD
George Aronoff, MD
Professor of Medicine and Pharmacology
Kidney Disease Program
University of Louisville School of Medicine
Chaim Charytan, MD
Chief, Renal Division
NewYork Hospital Medical Center of Queens
Clinical Professor of Medicine
Cornell University College of Medicine
David Van Wyck, MD
Professor of Medicine and Surgery
The University of Arizona
College of Medicine
Post-test and evaluation form are at
this link, but you must listen to all talks
from this symposium prior to completing the
CME: This activity has been planned and implemented in accordance with the
Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the Joint sponsorship of The University of Arizona College of Medicine at the Arizona Health
Sciences Center and American Regent Laboratories, Inc. The University of Arizona College of Medicine at the Arizona Health Sciences Center is accredited by the ACCME to provide continuing
medical education for physicians.
The University of Arizona College of Medicine at the Arizona Health
Sciences Center designates this educational activity for a maximum of 1.5 hours in category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of
credit that he/she actually spent in the activity.
CE: These talks are also designated to provide 1.5 hours of CE Nursing Education credits, sponsored
by the Renal Education Association. The Renal Education Association is accredited by
the State of California Board of Nursing to provide continuing education for nurses
(Provider number: CEP 13092).
Posting date: February, 2003.
Review date: February, 2004
in this self-study activity should be completed in approximately
two (1.5) hours. There are no fees for participating and receiving
CME or CE credit for this activity. To successfully complete
this activity and receive credit, participants must follow these
steps during the period February, 2003 through February, 2004.
INSTRUCTIONS FOR CREDIT :
1. Register for continuing education credit by completing the
2. Read the goals and learning objectives.
3. Read the article text and tables, and review figures.
4. Read, complete, and submit answers to the post test questions
and evaluation questions. You must receive a test score of at
least 75% and respond to all evaluation questions to receive
your online CME or CE certificate.
primary target audience is physicians involved in the care of renal patients (CME), and nephrology nurses, dietitians,
dialysis technicians and pharmacists (CE).
faculty participating in continuing medical education programs
are expected to disclose to the program audience any real or
apparent conflict of interest related to the subject under discussion.
The faculty disclosure information is as follows:
DISCLOSURE STATEMENTS :
Aaronson, Michael: received research funding, honoraria, or
served on an advisory board for; American Regent, Amgen, Astra-Zeneca,
Aventis, Boehringer-Ingelheim, Eli Lilly, Merch, Novartis, Ortho-Biotech,
Parke-Davis, Pfizer, Pharmacia & Upjohn
Aronoff, George: received research funding, honoraria, or served
on an advisory board for American Regent, Amgen, Astra-Zeneca,
Aventis, Boehringer-Ingelheim, Eli Lilly, Merck, Novartis, Ortho
Biotech, Clarke-Davis, Pfizer, Pharmacia-Upjohn, Schein, Solvay
Chaim: received research funding, honoraria, or served
on an advisory board for Amgen, Ortho, Am Regent, Ortho Biotech.
Van Wyck, David: is a member of the Speakers Bureau for American
Regent Labs, Inc. and Amgen, Inc.
educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by FDA.
The University of Arizona, HDCN and the Renal Education Association do not recommend the
use of any agent outside of the labeled indications. Please
refer to the official prescribing information for each product
for discussion of approved indications, contraindications and
DISCLOSURE OF UNLABELED USE: